Navigation Links
European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Date:4/3/2013

DALLAS, April 3, 2013 /PRNewswire/ --

The European Nuclear Medicine / Radiopharmaceuticals Market[SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017].

Browse >>

  • 133  market data tables
  • 29  figures
  • 292  pages and an in-depth Table of Content on "European Nuclear Medicine / Radiopharmaceuticals Market "

http://www.marketsandmarkets.com/Market-Reports/european-nuclear-medicine-radiopharmaceuticals-market-1107.html

Early buyers will receive 10% customization on this report.

This report studies the European nuclear medicine market over the forecast period 2012-2017.

The European radiopharmaceutical market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion by 2017 at a CAGR of 6.8%.

The radioisotopes market is categorized into diagnostic and therapeutic applications. The diagnostic market consists of PET and SPECT technologies, while the therapy market comprises of beta emitters and brachytherapy seeds. The SPECT market accounted for a major share of the diagnostic segment in 2012. Significant radioisotopes in the SPECT diagnostic market are Tc-99m, Tl- 201, Ga-67, and I-123, while PET market is dominated by F-18 and Rb-82. The therapy market is led by I-131, Sm-153, Re-186, Y-90, and Lu-177. Alpha emitters are being developed and considered for cancer treatment, however not available commercially.

It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 15% in mature markets of Europe, and other developed regions between 2010 and 2030, however shortage of Mo-99/Tc-99m has been a threat to this industry. The scheduled shutdown of the NRU reactor in Canada in 2016 and OSIRIS in France in 2018 is a major risk for manufacturers in the near future. Companies have increased the production of thallium to meet the shortage, as it is the most commonly used substitute for technetium-99 in cardiac-stress tests, conducted to evaluate the functioning of coronary arteries. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and other factors such as rising awareness of radiopharmaceuticals among physicians, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons have driven the market. High cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals are major hurdles to growth of the market.

Germany is the dominant market for diagnostic radioisotopes with 25% share. Over 120 PET-CT facilities contributed significantly to the German market in 2012; the region had around 600 gamma cameras and 76 PET (PET/CT) scanners. Cross sectional imaging like SPECT (SPECT/CT) and PET (PET/CT) are majorly preferred. Among different European countries, Russia, Turkey, and Czech Republic will be significant due to rising healthcare budgets and increasing popularity of different European nuclear medicine market in various clinical indications. Processors such as Covidien Plc., and other players from different geographies run reactors that are involved in the irradiation of U-235 to make crude isotopes. They follow various strategies to achieve sustainable growth, one of which is shifting to Low Enriched Uranium (LEU) from High Enriched Uranium (HEU). These key players were mainly involved in strategic agreements and contracts with other institutes and players, while generator manufacturers followed several strategies to maintain a sustainable supply chain.

The stable isotopes market was less than $25 million in 2012 and poised to grow at more than 8.0% CAGR in the next 5 years. Carbon-13 commanded the largest share of the European stable isotope market in 2012; however deuterium and oxygen show tremendous potential to grow in the near future. The market was dominated by two players, Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) in 2012 jointly contributing more than 50% to the European stables revenue.

Buy a copy of this report @http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=1107

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets



'/>"/>
SOURCE MarketsandMarkets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
5. Mylan Launches Generic Lipitor® in Five European Countries
6. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
7. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
10. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... 25, 2016 Digital Health Dialog, LLC ... by the US Patent and Trademark Office of ... proprietary processes for electronic opt-­in and processing of ... programs, HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... May 2016 – Lips ... central to popular cosmetic improvement efforts. Record numbers of clients now ask about lip ... or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , The ...
(Date:5/26/2016)... ... May 26, 2016 , ... In 1980, Bill Howe ... calls throughout the beach community. His vision to grow the company was built on ... they maintain the highest level of training and customer service. Over 35 years later, ...
(Date:5/26/2016)... SAN DIEGO, California (PRWEB) , ... May 26, ... ... to Santa Barbara this Memorial Day weekend to host their second pop-up shop ... the San Diego fashion forward brand to the Santa Barbara community, a community ...
(Date:5/25/2016)... Francisco, CA (PRWEB) , ... May 26, 2016 , ... ... 2016, from 6pm to 7.30pm PST at HP in Palo Alto, CA. This Bay ... discussion will be led by clinical trial experts from the pharmaceutical company Hallux, biopharma ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Furthering its position ... athletics, The National Center for Drug Free Sport (Drug Free Sport®) is excited to ... conference, to be held July 12 – 13 in Kansas City, MO, will gather ...
Breaking Medicine News(10 mins):